Paclitaxel Tumor-Priming Enhances siRNA Delivery and Transfection in 3-Dimensional Tumor Cultures
Authors:
- 21 March 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 8 (3) , 833-840
Abstract
The clinical development of siRNA cancer therapeutics is limited by the poor interstitial transport and inefficient transfection in solid tumors. We have shown that paclitaxel pretreatment, by inducing apoptosis, causes expansion of the interstitial space and thereby improves nanoparticle delivery and transport in tumor interstitium (referred to as paclitaxel tumor priming) and efficacy of nanomedicines in tumor-bearing animals. The present study evaluated whether paclitaxel tumor priming improves the delivery and transfection of siRNA in 2- and 3-dimensional cultures of human oropharyngeal carcinoma FaDu cells. We used the fluorescent siGLO and confocal microcopy to monitor transport, and used survivin siRNA and immunostaining and immunoblotting to monitor transfection. Survivin is a chemoresistance gene/protein, inducible by chemotherapy. siRNA was loaded in cationic liposomes. The results showed that pretreatment with 50−200 nM paclitaxel (24 or 48 h before siRNA) enhanced the total uptake of siGLO into monolayers (∼15%, p < 0.05), and the depth of penetration into 3-dimensional spheroids and tumor fragment histocultures (2.1- to 2.5-times greater area under the penetration-depth curve). In both monolayer cells and histocultures, paclitaxel pretreatment induced survivin upregulation (p < 0.05). Survivin siRNA alone decreased the survivin levels in a dose-dependent manner, and applying survivin siRNA after paclitaxel pretreatment completely abolished the paclitaxel-induced survivin increases. These findings indicate that paclitaxel tumor priming did not compromise the siRNA functionality. In summary, paclitaxel tumor priming improved the penetration, transfection and functionality of siRNA in tumors, thus offering a promising and practical means to develop chemo-siRNA cancer gene therapy.Keywords
This publication has 29 references indexed in Scilit:
- Systemic siRNA delivery via hydrodynamic intravascular injectionAdvanced Drug Delivery Reviews, 2007
- Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applicationsAdvanced Drug Delivery Reviews, 2007
- Antibody constructs in cancer therapyCancer, 2007
- Targeted Delivery of Antisense Oligodeoxynucleotide and Small Interference RNA into Lung Cancer CellsMolecular Pharmaceutics, 2006
- Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinomaCancer Biology & Therapy, 2006
- Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1Annals of Oncology, 2006
- RNA interference against Hec1 inhibits tumor growth in vivoGene Therapy, 2005
- Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer TherapyClinical Cancer Research, 2004
- Regional heterogeneity and pharmacodynamics in human solid tumor histocultureCancer Chemotherapy and Pharmacology, 1999
- Determinants of Paclitaxel Penetration and Accumulation in Human Solid TumorThe Journal of Pharmacology and Experimental Therapeutics, 1999